news flash·2025-07-28 09:26Core Viewpoint - Fosun Pharma has signed a licensing agreement with Newco to develop the AR1001 drug for Alzheimer's disease and other neurological disorders in China and Hong Kong, marking a significant step in the company's expansion into this therapeutic area [1] Group 1: Licensing Agreement Details - Fosun Pharma's subsidiary will pay up to 150 million yuan as an upfront payment and regulatory milestone payments for the rights to develop, register, produce, and commercialize AR1001 in the specified regions [1] - The agreement covers the diagnosis, prevention, and treatment of Alzheimer's disease and other neurological disorders [1] Group 2: Market Context - As of the date of the announcement, there are no approved drugs targeting the same mechanism for treating Alzheimer's disease globally, highlighting the potential market opportunity for AR1001 [1]